Vera Therapeutics VERA
$25.45 −$1.30 (-4.86%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $24.88 -2.24%
Open$26.37
Prev close$26.75
Day range$25.16 – $27.15
Volume1.37M
Market cap$1.84B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$10.28M
Operating profit-$95.70M-14.0% YoY
Net profit-$93.71M-16.7% YoY
Diluted EPS-$1.30-3.2% YoY
Free cash flow-$99.59M-60.5% YoY
Operating cash flow-$99.18M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin67.9%
Operating margin-4,160.1%
Net margin-4,041.2%
Return on equity-113.5%
Return on assets-84.5%
Return on invested capital-97.0%
Current ratio7.91
Liabilities / assets28.5%
Cash & investments$384.04M
Total debt$76.79M
Net cash (debt)$307.25M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $10.28M | – | – | – | – |
| Total Operating Revenue | $10.28M | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $3.30M | – | – | – | – |
| Gross Profit | $6.98M | – | – | – | – |
| Operating Expense | $102.68M | $112.49M | $125.13M | $315.47M | $94.21M |
| Selling and Admin Expenses | $61.43M | $52.41M | $39.12M | $100.22M | $34.90M |
| -Selling & Marketing Expense | $15.87M | – | – | – | – |
| -General & Admin Expense | $45.57M | $52.41M | $39.12M | $100.22M | $45.68M |
| Research & Development | $41.25M | $60.08M | $86.01M | $215.26M | $59.31M |
| Operating Profit | -$95.70M | -$112.49M | -$125.13M | -$315.47M | -$94.21M |
| Net Non-Operating Interest Income (Expense) | $2.46M | $3.50M | $4.53M | $16.95M | $3.61M |
| Non-Operating Interest Income | $4.34M | $5.35M | $6.36M | $24.48M | $5.52M |
| Non-Operating Interest Expense | $1.87M | $1.85M | $1.82M | $7.53M | $1.90M |
| Other Income (Expense) | -$472,000.00 | -$483,000.00 | -$432,000.00 | -$1.09M | -$503,000.00 |
| Other Non-Operating Income (Expenses) | -$472,000.00 | -$483,000.00 | -$432,000.00 | -$1.09M | -$503,000.00 |
| Pretax Profit | -$93.71M | -$109.47M | -$121.03M | -$299.61M | -$91.10M |
| Net Profit | -$93.71M | -$109.47M | -$121.03M | -$299.62M | -$91.10M |
| Profit from Continuing Operations | -$93.71M | -$109.47M | -$121.03M | -$299.62M | -$91.10M |
| Net Income to Parent Company | -$93.71M | -$109.47M | -$121.03M | -$299.62M | -$91.10M |
| Net Income to Common Stockholders | -$93.71M | -$109.47M | -$121.03M | -$299.62M | -$91.10M |
| Basic EPS | -$1.30 | -$1.52 | -$1.69 | -$4.66 | -$1.39 |
| Diluted EPS | -$1.30 | -$1.52 | -$1.69 | -$4.66 | -$1.39 |
| Tax | – | – | – | $1,000.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $465.75M | $532.98M | $621.74M | $734.73M | $734.73M |
| Total Current Assets | $441.29M | $527.49M | $615.80M | $728.88M | $728.88M |
| Cash and Cash Equivalents & Short-Term Investments | $384.04M | $499.16M | $596.76M | $714.59M | $714.59M |
| -Cash and Cash Equivalents | $55.32M | $48.88M | $114.35M | $354.73M | $354.73M |
| -Short Term Investments | $328.72M | $450.29M | $482.41M | $359.86M | $359.86M |
| Receivables | $14.57M | $3.93M | $3.91M | $3.29M | $3.29M |
| -Accounts Receivable | $11.98M | – | – | – | – |
| -Accrued Interest Receivable | $2.59M | $3.93M | $3.91M | $3.29M | $3.29M |
| Prepaid Assets | $28.69M | $20.20M | $12.64M | $8.47M | $8.47M |
| Inventory | $7.08M | – | – | – | – |
| Other Current Assets | $6.91M | $4.21M | $2.50M | $2.54M | $2.54M |
| Total Non-Current Assets | $24.47M | $5.49M | $5.94M | $5.85M | $5.85M |
| Goodwill and Other Intangible Assets | $20.50M | – | – | – | – |
| -Other Intangible Assets | $20.50M | – | – | – | – |
| Other Non-Current Assets | $3.97M | $5.49M | $5.94M | $2.55M | $2.55M |
| Total Liabilities | $132.57M | $125.23M | $122.04M | $130.21M | $130.21M |
| Total Current Liabilities | $55.78M | $48.32M | $45.15M | $53.46M | $53.46M |
| Payables | $20.17M | $14.57M | $13.91M | $21.90M | $21.90M |
| -Accounts Payable | $20.17M | $14.57M | $13.91M | $21.90M | $21.90M |
| Current Accrued Expenses | $32.78M | $31.02M | $27.77M | $29.64M | $29.64M |
| Other Current Liabilities | $2.82M | $2.73M | $3.47M | $1.37M | $1.37M |
| Total Non-Current Liabilities | $76.79M | $76.91M | $76.89M | $76.76M | $76.76M |
| Long Term Debt and Capital Lease Obligation | $76.79M | $76.91M | $76.89M | $76.76M | $76.76M |
| -Long Term Debt | $75.43M | $75.23M | $75.03M | $74.84M | $74.84M |
| -Long Term Capital Lease Obligation | $1.36M | $1.68M | $1.86M | $1.92M | $1.92M |
| Total Equity | $333.19M | $407.76M | $499.70M | $604.52M | $604.52M |
| Stockholders' Equity | $333.19M | $407.76M | $499.70M | $604.52M | $604.52M |
| Capital Stock | $72,000.00 | $72,000.00 | $72,000.00 | $71,000.00 | $71,000.00 |
| -Common Stock | $72,000.00 | $72,000.00 | $72,000.00 | $71,000.00 | $71,000.00 |
| Additional Paid-In Capital | $1.42B | $1.40B | $1.38B | $1.36B | $1.36B |
| Retained Earnings | -$1.09B | -$991.37M | -$881.90M | -$760.87M | -$760.87M |
| Gains/Losses Not Affecting Retained Earnings | -$704,000.00 | -$403,000.00 | -$156,000.00 | $786,000.00 | $786,000.00 |
| Net PPE | – | – | – | $3.30M | $3.30M |
| -Gross PPE | – | – | – | $3.30M | $3.30M |
| -Due to Related Parties Current | – | – | – | $3,000.00 | $3,000.00 |
| Short-Term Debt and Capital Lease Obligation | – | – | – | $549,000.00 | $549,000.00 |
| -Current Capital Lease Obligation | – | – | – | $549,000.00 | $549,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$99.18M | -$100.25M | -$106.50M | -$241.10M | -$69.99M |
| Net cash flow from continuing operations | -$99.18M | -$100.25M | -$106.50M | -$241.10M | -$69.99M |
| Net Income from Continuing Operations | -$93.71M | -$109.47M | -$121.03M | -$299.62M | -$91.10M |
| Depreciation & Depletion & Amortization | $823,000.00 | $132,000.00 | $140,000.00 | $468,000.00 | $135,000.00 |
| Other Non-Cash Items | $778,000.00 | $766,000.00 | $15.76M | $4.11M | $750,000.00 |
| Change in Working Capital | -$21.74M | -$6.44M | -$13.73M | $22.99M | $10.36M |
| -Change in Prepaid Assets | -$9.78M | -$9.43M | -$5.14M | -$3.93M | -$422,000.00 |
| -Change in Payables and Accrued Expense | $7.11M | $3.17M | -$8.40M | $28.35M | $10.83M |
| -Change in Other Current Liabilities | -$4,000.00 | -$187,000.00 | -$182,000.00 | -$1.48M | -$100,000.00 |
| Net cash flow from investing | $101.91M | $32.86M | -$137.82M | $194.29M | $80.66M |
| Net Cash Flow from Continuing Investing Activities | $101.91M | $32.86M | -$137.82M | $194.29M | $80.66M |
| Net PPE Purchase and Sale | $0.00 | $0.00 | -$23,000.00 | -$630,000.00 | -$102,000.00 |
| Net Intangibles Purchase and Sale | -$409,000.00 | -$114,000.00 | -$150,000.00 | – | – |
| Net Investment Purchase and Sale | $122.32M | $32.97M | -$122.64M | $195.72M | $80.77M |
| Net Other Investing Changes | -$20.00M | $0.00 | -$15.00M | -$800,000.00 | $0.00 |
| Financing Cash Flow | $3.71M | $1.92M | $3.94M | $308.90M | $286.28M |
| Net Cash Flow from Continuing Financing Activities | $3.71M | $1.92M | $3.94M | $308.90M | $286.28M |
| Net Issuance Payments Of Debt | $0.00 | – | – | $23.34M | $0.00 |
| Proceeds from Stock Option Exercised | $3.71M | $1.92M | $3.94M | $6.98M | $4.19M |
| Ending Cash Balance | $55.32M | $48.88M | $114.35M | $354.73M | $354.73M |
| Net Change in Cash | $6.45M | -$65.48M | -$240.37M | $262.08M | $296.95M |
| Beginning Cash Balance | $48.88M | $114.35M | $354.73M | $92.65M | $57.77M |
| Free Cash Flow | -$99.59M | -$100.37M | -$106.67M | -$241.73M | -$70.10M |
| -Change in Other Current Assets | – | $0.00 | $0.00 | $51,000.00 | $1,000.00 |
| Net Common Stock Issuance | – | – | – | $300.50M | $300.50M |
| Net Other Financing Charges | – | – | – | -$21.92M | -$18.41M |
No comments yet — be the first to weigh in on VERA.
Sign in to join the discussion.